IL13RA2 and colorectal carcinoma: In support of this mechanism, inhibition of ligand–receptor binding using a synthetic peptide or blocking the scaffold protein FAM 120A, necessary for IL13Rα2-mediated signaling, has demonstrated antimetastatic activity in vitro and in vivo as well as an augmented survival to CRC in vivo [109,110].